PDF(Pubmed)
Abstract：
Risk prediction for subsequent cardiovascular events remains an unmet clinical issue in patients with coronary artery disease. We aimed to investigate prognostic metabolic biomarkers by considering both shared and distinct metabolic disturbance associated with the composite and individual cardiovascular events. Here, we conducted an untargeted metabolomics analysis for 333 incident cardiovascular events and 333 matched controls. The cardiovascular events were designated as cardiovascular death, myocardial infarction/stroke and heart failure. A total of 23 shared differential metabolites were associated with the composite of cardiovascular events. The majority were middle and long chain acylcarnitines. Distinct metabolic patterns for individual events were revealed, and glycerophospholipids alteration was specific to heart failure. Notably, the addition of metabolites to clinical markers significantly improved heart failure risk prediction. This study highlights the potential significance of plasma metabolites on tailed risk assessment of cardiovascular events, and strengthens the understanding of the heterogenic mechanisms across different events.
摘要：
在冠心病患者中，后续心血管事件的风险预测仍然是一个未解决的临床问题。我们旨在通过考虑与复合和个体心血管事件相关的共有和不同的代谢紊乱来研究预后代谢生物标志物。这里,我们对333例心血管事件和333例匹配对照进行了非靶向代谢组学分析.心血管事件被指定为心血管死亡，心肌梗死/中风和心力衰竭。共有23种共有的差异代谢物与心血管事件的复合相关。大多数是中链和长链酰基肉碱。揭示了单个事件的不同代谢模式，甘油磷脂的改变是心力衰竭特有的。值得注意的是,在临床标志物中添加代谢物显著改善了心力衰竭风险预测.这项研究强调了血浆代谢物对心血管事件尾部风险评估的潜在意义。并加强对不同事件间异质机制的理解。
